Abiraterone acetate (AA) in pre- and post-docetaxel (DX) setting for metastatic castration resistant prostate cancer (mCRPC): a monoinstitutional experience focused on cardiovascular events and on their impact on clinical outcomes

Creators: Boccardo, F; Cavo, A; Zanardi, E; Fabbroni, C; Zinoli, L; Di Meglio, A; Arboscello, E; Bellodi, A; Spallarossa, P; Cattrini, C; Messina, C; Rubagotti, A

Others:: Boccardo, F; Cavo, A; Zanardi, E; Fabbroni, C; Zinoli, L; Di Meglio, A; Arboscello, E; Bellodi, A; Spallarossa, P; Cattrini, C; Messina, C; Rubagotti, A

Additional details